Pegaptanib sodium

被引：66
作者：
Fine, SL
Martin, DF
Kirkpatrick, P
机构：
[1] Univ Penn, Dept Ophthalmol, Scheie Eye Inst, Hlth Syst, Philadelphia, PA 19104 USA
[2] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2005年 / 4卷 / 03期
关键词：
D O I：
10.1038/nrd1677
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
In December 2004, pegaptanib sodium (Macugen; Eyetech/Pfizer), which targets vascular endothelial growth factor, was approved by the US FDA for the treatment of neovascular age-related macular degeneration. As well as being the first anti-angiogenic agent to be approved for this common eye disorder, it is also the first approved therapeutic based on an RNA structure known as an aptamer.
引用
收藏
页码：187 / 188
页数：2
相关论文
共 9 条
  • [1] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS
    AIELLO, LP
    AVERY, RL
    ARRIGG, PG
    KEYT, BA
    JAMPEL, HD
    SHAH, ST
    PASQUALE, LR
    THIEME, H
    IWAMOTO, MA
    PARK, JE
    NGUYEN, HV
    AIELLO, LM
    FERRARA, N
    KING, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) : 1480 - 1487
  • [2] Ophthalmic drug discovery
    Clark, AF
    Yorio, T
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (06) : 448 - 459
  • [3] Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
  • [4] The biology of VEGF and its receptors
    Ferrara, N
    Gerber, HP
    LeCouter, J
    [J]. NATURE MEDICINE, 2003, 9 (06) : 669 - 676
  • [5] Drug therapy: Age-related macular degeneration.
    Fine, SL
    Berger, JW
    Maguire, MG
    Ho, AC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (07) : 483 - 492
  • [6] Pegaptanib for neovascular age-related macular degeneration
    Gragoudas, ES
    Adamis, AP
    Cunningham, ET
    Feinsod, M
    Guyer, DR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2805 - 2816
  • [7] A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss - AREDS Report No. 8
    Kassoff, A
    Kassoff, J
    Buehler, J
    Eglow, M
    Kaufman, F
    Mehu, M
    Kieval, S
    Mairs, M
    Graig, B
    Quattrocchi, A
    Jones, D
    Locatelli, J
    Ruby, A
    Capone, A
    Garretson, B
    Hassan, T
    Trese, MT
    Williams, GA
    Regan, V
    Manatrey, P
    Streasick, P
    Szydlowski, L
    McIver, F
    Bridges, C
    Stanley, C
    Cumming, K
    Lewis, B
    Zajechowski, M
    Margherio, RR
    Cox, MS
    Camille, J
    Falk, R
    Siedlak, P
    Neubert, C
    Klein, ML
    Stout, JT
    O'Malley, A
    Lauer, AK
    Robertson, JE
    Wilson, DJ
    Beardsley, C
    Anderson, H
    Wallace, P
    Smith, G
    Howard, S
    Dreyer, RF
    Ma, C
    Chenoweth, RG
    Zilis, JD
    Johnson, M
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2001, 119 (10) : 1417 - 1436
  • [8] 2′-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165) -: Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain
    Ruckman, J
    Green, LS
    Beeson, J
    Waugh, S
    Gillette, WL
    Henninger, DD
    Claesson-Welsh, L
    Janjic, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (32) : 20556 - 20567
  • [9] 2004, FDA LABELLING INFORM
1